Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ELIZABETH J DAVIS

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1770711657
CMS profile
125381
Location
NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$3,850.00

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $3,850.00 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Deciphera Pharmaceuticals Inc. $3,850.00 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ELIZABETH J DAVIS

NPI 1770711657 · CMS profile ID 125381

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NASHVILLE, TN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1770711657?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ELIZABETH J DAVIS, NPI 1770711657, CMS profile ID 125381. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1770711657?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ELIZABETH J DAVIS, NPI 1770711657, CMS profile ID 125381. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1770711657?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ELIZABETH J DAVIS, NPI 1770711657, CMS profile ID 125381, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1770711657?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $3,850.00 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Deciphera Pharmaceuticals Inc. $3,850.0005/17/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826794865 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $3,850.00 1
PY2022 $4,356.15 12
PY2023 $3,523.13 2
PY2024 $10,278.04 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $262,678.16 31
PY2024 Principal investigator $275,878.05 33
PY2023 Principal investigator $251,134.21 62
PY2022 Principal investigator $72,761.84 12
PY2021 Principal investigator $94,885.25 18
PY2020 Principal investigator $87,370.36 35
PY2019 Principal investigator $196,644.78 43

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

43 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $1,395.00 12/19/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458489
Principal investigator 1 Incyte Corporation $3,045.00 12/19/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458491
Principal investigator 1 Genentech, Inc. $2,384.00 12/11/2019 Covered Recipient Teaching Hospital
VANDERBILT UNIVERSITY MEDICAL CENTER
MY PATHWAY A STUDY EVALUATING HERCEPTINPERJETA, TARCEVA, ZELBORAFCOTELLIC, ERIVEDGE, ALECENSA, AND TECENTRIQ TREATMENT TARGETED AGAINST CERTAIN MOLECULAR ALTERATIONS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 708837159
Principal investigator 1 Genentech, Inc. $2,840.00 11/19/2019 Covered Recipient Teaching Hospital
VANDERBILT UNIVERSITY MEDICAL CENTER
PHASE 1B OF PD LI IMMUNOTHERAPY No dispute reported 06/30/2026 681103045
Principal investigator 1 Genentech, Inc. $1,920.60 11/19/2019 Covered Recipient Teaching Hospital
VANDERBILT UNIVERSITY MEDICAL CENTER
PHASE 1B OF PD LI IMMUNOTHERAPY No dispute reported 06/30/2026 681110485
Principal investigator 1 Genentech, Inc. $1,294.52 10/15/2019 Covered Recipient Teaching Hospital
VANDERBILT UNIVERSITY MEDICAL CENTER
MY PATHWAY A STUDY EVALUATING HERCEPTINPERJETA, TARCEVA, ZELBORAFCOTELLIC, ERIVEDGE, ALECENSA, AND TECENTRIQ TREATMENT TARGETED AGAINST CERTAIN MOLECULAR ALTERATIONS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 708837033
Principal investigator 1 Incyte Corporation $500.00 10/09/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458469
Principal investigator 1 Genentech, Inc. $500.00 08/06/2019 Covered Recipient Teaching Hospital
VANDERBILT UNIVERSITY MEDICAL CENTER
PHASE 1B OF PD LI IMMUNOTHERAPY No dispute reported 06/30/2026 681099361
Principal investigator 1 Genentech, Inc. $6,749.00 08/01/2019 Covered Recipient Teaching Hospital
VANDERBILT UNIVERSITY MEDICAL CENTER
MY PATHWAY A STUDY EVALUATING HERCEPTINPERJETA, TARCEVA, ZELBORAFCOTELLIC, ERIVEDGE, ALECENSA, AND TECENTRIQ TREATMENT TARGETED AGAINST CERTAIN MOLECULAR ALTERATIONS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 708836773
Principal investigator 1 Genentech, Inc. $5,031.00 07/30/2019 Covered Recipient Teaching Hospital
VANDERBILT UNIVERSITY MEDICAL CENTER
MY PATHWAY A STUDY EVALUATING HERCEPTINPERJETA, TARCEVA, ZELBORAFCOTELLIC, ERIVEDGE, ALECENSA, AND TECENTRIQ TREATMENT TARGETED AGAINST CERTAIN MOLECULAR ALTERATIONS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 708836533
Principal investigator 1 Incyte Corporation $18,479.91 07/12/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458305
Principal investigator 1 Incyte Corporation $83.80 07/12/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458309
Principal investigator 1 Incyte Corporation $500.00 07/12/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458435
Principal investigator 1 Genentech, Inc. $647.26 07/11/2019 Covered Recipient Teaching Hospital
VANDERBILT UNIVERSITY MEDICAL CENTER
MY PATHWAY A STUDY EVALUATING HERCEPTINPERJETA, TARCEVA, ZELBORAFCOTELLIC, ERIVEDGE, ALECENSA, AND TECENTRIQ TREATMENT TARGETED AGAINST CERTAIN MOLECULAR ALTERATIONS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 708836429
Principal investigator 1 Incyte Corporation $95.00 07/01/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458209
Principal investigator 1 Genentech, Inc. $5,031.00 06/20/2019 Covered Recipient Teaching Hospital
VANDERBILT UNIVERSITY MEDICAL CENTER
MY PATHWAY A STUDY EVALUATING HERCEPTINPERJETA, TARCEVA, ZELBORAFCOTELLIC, ERIVEDGE, ALECENSA, AND TECENTRIQ TREATMENT TARGETED AGAINST CERTAIN MOLECULAR ALTERATIONS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 708836843
Principal investigator 1 Incyte Corporation $645.00 06/11/2019 Non-covered Recipient Entity
VANDERBILT MED CTR
A Phase 12, Open Label, Dose Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies ECHO 208 No dispute reported 06/30/2026 666475171
Principal investigator 1 Incyte Corporation $1,500.00 06/11/2019 Non-covered Recipient Entity
VANDERBILT MED CTR
A Phase 12, Open Label, Dose Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies ECHO 208 No dispute reported 06/30/2026 666475173
Principal investigator 1 Incyte Corporation $2,000.00 06/11/2019 Non-covered Recipient Entity
VANDERBILT MED CTR
A Phase 12, Open Label, Dose Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies ECHO 208 No dispute reported 06/30/2026 666475175
Principal investigator 1 Incyte Corporation $95.00 06/01/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458205
Principal investigator 1 Genentech, Inc. $1,395.00 05/29/2019 Covered Recipient Teaching Hospital
VANDERBILT UNIVERSITY MEDICAL CENTER
PHASE 1B OF PD LI IMMUNOTHERAPY No dispute reported 06/30/2026 681083163
Principal investigator 1 Incyte Corporation $20.93 05/08/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies ECHO 208 No dispute reported 06/30/2026 666458081
Principal investigator 1 Incyte Corporation $95.00 05/01/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458201
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,845.00 04/23/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors No dispute reported 06/30/2026 686160441
Principal investigator 1 Incyte Corporation $310.06 04/19/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458263
Principal investigator 1 Incyte Corporation $23,824.37 04/05/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458249
Principal investigator 1 Incyte Corporation $889.23 04/05/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458251
Principal investigator 1 Incyte Corporation $1,613.00 04/05/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458253
Principal investigator 1 Incyte Corporation $2,644.50 04/05/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458255
Principal investigator 1 Incyte Corporation $194.04 04/05/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458257
Principal investigator 1 Incyte Corporation $7,200.00 04/05/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458259
Principal investigator 1 Incyte Corporation $87,748.55 04/05/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458261
Principal investigator 1 Incyte Corporation $95.00 04/01/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458197
Principal investigator 1 Genentech, Inc. $1,941.78 03/27/2019 Covered Recipient Teaching Hospital
VANDERBILT UNIVERSITY MEDICAL CENTER
MY PATHWAY A STUDY EVALUATING HERCEPTINPERJETA, TARCEVA, ZELBORAFCOTELLIC, ERIVEDGE, ALECENSA, AND TECENTRIQ TREATMENT TARGETED AGAINST CERTAIN MOLECULAR ALTERATIONS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS No dispute reported 06/30/2026 708836923
Principal investigator 1 Incyte Corporation $500.00 03/12/2019 Non-covered Recipient Entity
VANDERBILT MED CTR
A Phase 12, Open Label, Dose Escalation, Safety, Tolerability, and Efficacy Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies ECHO 208 No dispute reported 06/30/2026 666475167
Principal investigator 1 Incyte Corporation $95.00 03/01/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458217
Principal investigator 1 Incyte Corporation $95.00 02/01/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458213
Principal investigator 1 Incyte Corporation $7,516.92 01/26/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458235
Principal investigator 1 Incyte Corporation $129.00 01/26/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458237
Principal investigator 1 Incyte Corporation $1,507.57 01/26/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458239
Principal investigator 1 Incyte Corporation $1,395.00 01/26/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458241
Principal investigator 1 Incyte Corporation $758.74 01/26/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458243
Principal investigator 1 Incyte Corporation $95.00 01/01/2019 Non-covered Recipient Entity
VANDERBILT UNIVERSITY MEDICAL CENTER
A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 666458193